Exploring the Next Generation of Metabolic Health Innovations
About this episode
Cade Archibald discusses emerging developments in metabolic health, focusing on two investigational therapies and the importance of individualized treatment decisions.
In this episode of the Ageless Future Podcast , Cade Archibald explores emerging developments in metabolic health, comparing two investigational therapies—an oral GLP-1 medication (orforglipron) and the injectable triple-agonist retatrutide. The discussion highlights how these therapies differ in delivery methods, mechanisms of action, and areas of ongoing clinical research, while emphasizing that treatment decisions should be individualized and made with a healthcare provider. The episode also encourages listeners to look beyond weight alone by tracking personal health metrics, adopting healthy nutrition and exercise habits, and staying informed about evolving research and wearable health technologies that support long-term wellness. RESOURCES: Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/ FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprint Sign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registration Books: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibald Blog: https://agelessfuture.com/learn/?e=newsletter Articles…
More episodes of Ageless Future
- Beyond Weight Loss: Exploring the Next Generation of Longevity Peptides
- Finding Joy in Movement: Exploring Exercise, Performance, and Daily Activity
- Exploring the Future of Regenerative Medicine: Research Perspectives on MUSE Cells and Longevity
Explore listener stats, chart rankings, contacts and more on the Ageless Future podcast page.